Phase 2 N=2 Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
Pancreatic Cancer Stage IV
Primary: Number of Participants With Progression Free Survival (PFS) — 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury
Muscle Injury · Recovery · Pain Relief
Primary: Self-report Ratings of Muscle Soreness — 0.0; 0.0 score on a scale
Phase 2 N=80 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Myelodysplastic Syndrome (MDS) · Chronic Lymphocytic Leukemia (CLL) · Chemotherapy-sensitive Lymphoma
Primary: Overall Survival — 72.3; 78.9 percentage of participants
Phase 2 N=52 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
Diabetic Macular Edema · Retinal Disease · Macular Edema
Primary: Mean Change From Baseline to Average of Week 20 and Week 24 in BCVA by ETDRS Letter — 5.1; 3.7 change in ETDRS letters
N/A N=60 Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)
Hypertension
Primary: Systolic Blood Pressure Readings — 144.3; 138.1; 136.8; 151.7 mmHg
N/A N=1,658 Prevention of Urinary Stones With Hydration
Urinary Stones
Primary: Number of Participants With a Symptomatic Stone Event — 154; 165 Participants
N/A N=120 Rehabilitation Robotic System ReHand
Stroke · Rehabilitation · Robotic Exoskeleton
Primary: Fugl-Meyer Assessment for Upper Extremity (FMA-UE) — 45.0; 36.0 score on a scale
N/A N=11 Feasibility of Meal Delivery Postpartum
Postpartum Weight Retention · Obesity
Primary: Self-Reported Proportion of Received Study Meals Consumed — 0.86; 0.05; 0.09 Proportion of Received Meals
N/A N=40 Artificial Intelligence + Care Coach Intervention
Dementia · Caregiver · Emergency Department
Primary: Intervention Appropriateness Measure — 15.1; 15.8 score on a scale
N/A N=423 Implementation of the Care Ecosystem Training Model for Individuals With Dementia in a High-risk, Integrated Care Management
Dementia · Alzheimer Disease
Primary: ED Visits Per Member Per Month 6 Months Post Intervention — 0.056; 0.075 Visits per member per month — p=0.05
Early Phase 1 N=12 Cocaine and Zolmitriptan
Cocaine Use Disorder
Primary: Reinforcing Effects of Cocaine — 1.4; 4; 4.5; 0.7 number of times subjects chose cocaine
N/A N=250 Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System
Peripheral Artery Disease
Primary: Number of Participants With Procedure Success — 232 Participants
N/A N=2,634 CONFIDENT: Supporting Long-term Care Workers During COVID-19
COVID-19
Primary: COVID-19 Vaccine Confidence — 93; 106; 138 Participants — p=0.99
N/A N=12 Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder
Multiple Sclerosis · Lower Urinary Tract Symptoms · Neurogenic Bladder
Primary: Change in Blood Oxygen Level Dependent (BOLD) Signals in the Brain After Treatment — 2.6; 2.6; 3.5; 2.6 BOLD Signal Change Derived T-Value — p=0.0012
Phase 4 N=58 Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
Schizophrenia · Schizoaffective Disorder
Primary: Cognition Measured by AX-Continuous Performance Test (AX-CPT) D-prime Score — 2.7; 2.5; 2.3; 3.2 d prime score — p=<0.016